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There is an increasing interest on the effectiveness of azacitidine
for the treatment of higher-risk myelodysplastic syndromes (MDS)
outside clinical trials. We recently reported the lack of effect
of this drug in an unselected population of 821 patients.1 In
response to our work, Dinmohamed et al.2 have performed a
similar retrospective analysis of a cohort including 121 patients
with higher-risk MDS included in the Dutch registry and treated
with either chemotherapy, azacitidine or best supportive care
(BSC). Both studies are aimed to analyze the potential effect
of the different treatment alternatives on overall survival (OS) in
large population-based registries of higher-risk MDS patients.
A common ﬁnding in both series is the lack of a survival
advantage of azacitidine compared with intensive chemotherapy.
However, in contrast to our results, azacitidine-treated patients
in the Dutch study showed an OS 9.3 months longer than those
who received BSC. This difference was statistically signiﬁcant only
in those patients who were classiﬁed as responders. Interestingly,
and resembling our ﬁndings, the subgroup of patients with
chromosome 7 abnormalities were the subgroup of patients with
an apparently more pronounced beneﬁt. The readership of
Leukemia should be aware that there are some relevant
methodological differences between both studies that could
explain their different results.
First, the comparison between treatment alternatives used
different statistical tests. The impact of treatment with azacitidine
on outcomes was studied by considering this variable as a time-
dependent covariate in our study but not in the Dutch series,
which used the classical Kaplan–Meier actuarial survival method.
We feel that the use of the time of starting treatment as starting
point in survival curves for azacitidine- and BSC-treated cohorts
introduces a bias against the BSC cohort because some patients
who were candidates for receiving azacitidine and died before
being treated with azacitidine are in fact, by Kaplan–Meier
method, considered BSC-treated patients. In this sense, in the
Dutch report the median time from diagnosis to the onset of
therapy was 7 days in the BSC group as compared with 33 days in
the azacitidine group (Po0.001). Moreover, some patients
receiving azacitidine have been diagnosed up to 5 years before,
in contrast to a maximum delay of 102 days in the BSC group.
This suggests that those patients with a lower probability of
survival or with worse predictors of response to either
chemotherapy or azacitidine were assigned to the BSC group. In
fact, patients in the BSC arm in the Dutch report showed more
comorbidities and a lower percentage of good-risk cytogenetics
(P= 0.007 and 0.002, respectively). To establish whether differ-
ences in statistical methodology are the main cause of the
discrepant results between both reports, we would be grateful if
our Dutch colleagues could perform a time-dependent analysis of
the effect of azacitidine treatment. As can be seen in Figure 1,
when an incorrect Kaplan–Meier survival analysis is used,
azacitidine treatment seems to be clearly beneﬁcial.
A second critical difference between the Spanish and Dutch
series concerns the lower than expected OS in Dutch patients
receiving BSC. These patients showed a median OS of only
7.3 months compared with 11 months in the GESMD (Grupo
Español de Síndromes Mielodisplásicos) registry. As the baseline
characteristics in the two studies were closely similar, this striking
difference could be due to a different intensity of the supportive
care that could have a signiﬁcant impact on OS. Interestingly,
median survival in azacitidine-treated patients who did not show
any response to the drug was 12.3 months. This survival is much
closer to our BSC group and to the control group of the AZA-
AML-001 trial (11.5 months).3 As the management of the patients
included in a clinical trial is strictly protocolized according to the
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Figure 1. Survival curves of azacitidine treatment versus best supportive therapy (BSC, excluding chemotherapy). If a conventional Kaplan–
Meier is used (left), there are signiﬁcant differences between groups. However, when azacitidine is considered a time-dependent covariate
(right), these differences disappear.
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best available evidence, we can hypothesize that an optimal
supportive care could have yielded a survival beneﬁt similar to the
one achieved in patients with no response to other treatments,
including azacitidine. This contrasts with the hypothesis raised by
Dinmohamed et al.,2 suggesting that azacitidine could be
beneﬁcial even in the absence of a response to the drug
according to the International Working Group (IWG) criteria.
Although these two hypotheses are not mutually exclusive, the
contribution of a carefully applied standard care to the OS cannot
be underestimated.
Finally, the greater heterogeneity of the Spanish cohort, including
cases of chronic myelomonocytic leukemia, other myeloproliferative
neoplasms or acute myeloid leukemia (20–30% blasts), could also
explain some of the differences with the Dutch study. However,
a subgroup analysis restricted to only high-risk MDS patients did not
show the superiority of azacitidine compared with conventional
therapy.
In conclusion, we agree with Dinmohamed et al.,2 on the clear
need of population-based studies to conﬁrm the ﬁndings of clinical
trials in the real life setting. In addition, we remark the importance of
an appropriate statistical analysis and of establishing a standardized
clinical management for all the patients included in clinical trials, not
only for those receiving the active drug under evaluation.
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